132 related articles for article (PubMed ID: 23832494)
41. Interleukin-4 inhibits RANKL-induced expression of NFATc1 and c-Fos: a possible mechanism for downregulation of osteoclastogenesis.
Kamel Mohamed SG; Sugiyama E; Shinoda K; Hounoki H; Taki H; Maruyama M; Miyahara T; Kobayashi M
Biochem Biophys Res Commun; 2005 Apr; 329(3):839-45. PubMed ID: 15752732
[TBL] [Abstract][Full Text] [Related]
42. Trichostatin A inhibits osteoclastogenesis and bone resorption by suppressing the induction of c-Fos by RANKL.
Kim HN; Ha H; Lee JH; Jung K; Yang D; Woo KM; Lee ZH
Eur J Pharmacol; 2009 Nov; 623(1-3):22-9. PubMed ID: 19766111
[TBL] [Abstract][Full Text] [Related]
43. Tanshinone IIA inhibits osteoclast differentiation through down-regulation of c-Fos and NFATc1.
Kwak HB; Yang D; Ha H; Lee JH; Kim HN; Woo ER; Lee S; Kim HH; Lee ZH
Exp Mol Med; 2006 Jun; 38(3):256-64. PubMed ID: 16819284
[TBL] [Abstract][Full Text] [Related]
44. Apolipoprotein E inhibits osteoclast differentiation via regulation of c-Fos, NFATc1 and NF-κB.
Kim WS; Kim HJ; Lee ZH; Lee Y; Kim HH
Exp Cell Res; 2013 Feb; 319(4):436-46. PubMed ID: 23246654
[TBL] [Abstract][Full Text] [Related]
45. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
[TBL] [Abstract][Full Text] [Related]
46. Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts.
Kim MH; Ryu SY; Choi JS; Min YK; Kim SH
J Cell Physiol; 2009 Dec; 221(3):618-28. PubMed ID: 19653230
[TBL] [Abstract][Full Text] [Related]
47. Crocin inhibits RANKL-induced osteoclast formation and bone resorption by suppressing NF-κB signaling pathway activation.
Fu L; Pan F; Jiao Y
Immunobiology; 2017 Apr; 222(4):597-603. PubMed ID: 27871781
[TBL] [Abstract][Full Text] [Related]
48. G protein-coupled receptor 84 controls osteoclastogenesis through inhibition of NF-κB and MAPK signaling pathways.
Park JW; Yoon HJ; Kang WY; Cho S; Seong SJ; Lee HW; Yoon YR; Kim HJ
J Cell Physiol; 2018 Feb; 233(2):1481-1489. PubMed ID: 28574596
[TBL] [Abstract][Full Text] [Related]
49. Aldehydic components of cinnamon bark extract suppresses RANKL-induced osteoclastogenesis through NFATc1 downregulation.
Tsuji-Naito K
Bioorg Med Chem; 2008 Oct; 16(20):9176-83. PubMed ID: 18823786
[TBL] [Abstract][Full Text] [Related]
50. Iguratimod (T-614) suppresses RANKL-induced osteoclast differentiation and migration in RAW264.7 cells via NF-κB and MAPK pathways.
Gan K; Yang L; Xu L; Feng X; Zhang Q; Wang F; Tan W; Zhang M
Int Immunopharmacol; 2016 Jun; 35():294-300. PubMed ID: 27085680
[TBL] [Abstract][Full Text] [Related]
51. Ginsenoside Rb2 inhibits osteoclast differentiation through nuclear factor-kappaB and signal transducer and activator of transcription protein 3 signaling pathway.
Cong F; Liu J; Wang C; Yuan Z; Bi L; Liang J; Su K; Qiu Y; Song T; Fan J; Chao G
Biomed Pharmacother; 2017 Aug; 92():927-934. PubMed ID: 28605877
[TBL] [Abstract][Full Text] [Related]
52. Cetylpyridinium chloride inhibits receptor activator of nuclear factor-κB ligand-induced osteoclast formation.
Zheng T; Chen L; Noh AL; Yim M
Biol Pharm Bull; 2013; 36(4):509-14. PubMed ID: 23546287
[TBL] [Abstract][Full Text] [Related]
53. ATF3 modulates calcium signaling in osteoclast differentiation and activity by associating with c-Fos and NFATc1 proteins.
Jeong BC; Kim JH; Kim K; Kim I; Seong S; Kim N
Bone; 2017 Feb; 95():33-40. PubMed ID: 27829167
[TBL] [Abstract][Full Text] [Related]
54. Calycosin Suppresses RANKL-Mediated Osteoclastogenesis through Inhibition of MAPKs and NF-κB.
Quan GH; Wang H; Cao J; Zhang Y; Wu D; Peng Q; Liu N; Sun WC
Int J Mol Sci; 2015 Dec; 16(12):29496-507. PubMed ID: 26690415
[TBL] [Abstract][Full Text] [Related]
55. Effects of moderate intensity static magnetic fields on osteoclastic differentiation in mouse bone marrow cells.
Kim EC; Park J; Noh G; Park SJ; Noh K; Kwon IK; Ahn SJ
Bioelectromagnetics; 2018 Jul; 39(5):394-404. PubMed ID: 29709064
[TBL] [Abstract][Full Text] [Related]
56. Agelasine D suppresses RANKL-induced osteoclastogenesis via down-regulation of c-Fos, NFATc1 and NF-κB.
Kang MR; Jo SA; Yoon YD; Park KH; Oh SJ; Yun J; Lee CW; Nam KH; Kim Y; Han SB; Yu J; Rho J; Kang JS
Mar Drugs; 2014 Nov; 12(11):5643-56. PubMed ID: 25421321
[TBL] [Abstract][Full Text] [Related]
57. Genipin inhibits RANKL-induced osteoclast differentiation through proteasome-mediated degradation of c-Fos protein and suppression of NF-κB activation.
Lee CH; Kwak SC; Kim JY; Oh HM; Rho MC; Yoon KH; Yoo WH; Lee MS; Oh J
J Pharmacol Sci; 2014; 124(3):344-53. PubMed ID: 24646621
[TBL] [Abstract][Full Text] [Related]
58. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
[TBL] [Abstract][Full Text] [Related]
59. Nrf2 deficiency induces oxidative stress and promotes RANKL-induced osteoclast differentiation.
Hyeon S; Lee H; Yang Y; Jeong W
Free Radic Biol Med; 2013 Dec; 65():789-799. PubMed ID: 23954472
[TBL] [Abstract][Full Text] [Related]
60. Induction of c-Fos and NFATc1 during RANKL-stimulated osteoclast differentiation is mediated by the p38 signaling pathway.
Huang H; Chang EJ; Ryu J; Lee ZH; Lee Y; Kim HH
Biochem Biophys Res Commun; 2006 Dec; 351(1):99-105. PubMed ID: 17052691
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
